You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先聲藥業(2096.HK)逆勢漲近10% 與中科院上海藥物所就新冠治療新一代口服特效藥開發達成合作
格隆匯 11-18 11:01
格隆匯11月18日丨大市下跌之際,先聲藥業(2096.HK)今日盤中逆勢拉昇漲近10%,為連續第三日上漲,股價創8月初以來新高,市值超240億港元。先聲藥業17日宣佈與中國科學院上海藥物研究所等就抗新型冠狀病毒(SARS‑CoV‑2)新藥開發達成項目合作。候選分子具有成為新一代口服新冠特效藥的潛力,對包括德爾塔毒株在內的多種新冠變異毒株均有很強的抑制作用。根據協議安排,先聲藥業將獲得抗冠狀病毒候選新藥SIM0417系列在全球開發、生產及商業化的獨家權利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account